Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD
Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD rema...
Saved in:
Published in | Physiological reports Vol. 10; no. 11; pp. e15307 - n/a |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.06.2022
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD remain unclear. To this end, iron and Pi metabolism were tested in a mouse model of CKD (0.2% adenine) ± 0.5% FC for 6 weeks, with and without osteocyte deletion of Fgf23 (flox‐Fgf23/Dmp1‐Cre). Intact FGF23 (iFGF23) increased in all CKD mice but was lower in Cre+ mice with or without FC, thus the Dmp1‐Cre effectively reduced FGF23. Cre+ mice fed AD‐only had higher serum Pi than Cre− pre‐ and post‐diet, and the Cre+ mice had higher BUN regardless of FC treatment. Total serum iron was higher in all mice receiving FC, and liver Tfrc, Bmp6, and hepcidin mRNAs were increased regardless of genotype; liver IL‐6 showed decreased mRNA in FC‐fed mice. The renal 1,25‐dihydroxyvitamin D (1,25D) anabolic enzyme Cyp27b1 had higher mRNA and the catabolic Cyp24a1 showed lower mRNA in FC‐fed mice. Finally, mice with loss of FGF23 had higher bone cortical porosity, whereas Raman spectroscopy showed no changes in matrix mineral parameters. Thus, FC‐ and FGF23‐dependent and ‐independent actions were identified in CKD; loss of FGF23 was associated with higher serum Pi and BUN, demonstrating that FGF23 was protective of mineral metabolism. In contrast, FC maintained serum iron and corrected inflammation mediators, potentially providing ancillary benefit.
Chronic kidney disease (CKD) affects 10% of the world population and results in many patient complications, including iron deficiency and hyperphosphatemia, both potent stimulators of the phosphaturic hormone FGF23. An iron‐containing phosphate binder, ferric citrate (FC), was developed to alleviate these manifestations, however, the impact of FC on FGF23‐ and iron‐mediated effects in CKD are not completely understood. This study provides novel insight into the FGF23‐ and iron‐mediated effects in CKD. We demonstrate that FGF23 is necessary to control phosphate and disease progression (monitored by BUN) in CKD. This study also supports that FC may improve 1,25D metabolism independent of FGF23 and lower markers of inflammation due to iron repletion. Therefore, FC may provide ancillary benefits which could lead to improved CKD patient outcomes. |
---|---|
AbstractList | Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD remain unclear. To this end, iron and Pi metabolism were tested in a mouse model of CKD (0.2% adenine) ± 0.5% FC for 6 weeks, with and without osteocyte deletion of
Fgf23
(flox‐Fgf23/Dmp1‐Cre). Intact FGF23 (iFGF23) increased in all CKD mice but was lower in Cre
+
mice with or without FC, thus the Dmp1‐Cre effectively reduced FGF23. Cre
+
mice fed AD‐only had higher serum Pi than Cre
−
pre‐ and post‐diet, and the Cre
+
mice had higher BUN regardless of FC treatment. Total serum iron was higher in all mice receiving FC, and liver Tfrc, Bmp6, and hepcidin mRNAs were increased regardless of genotype; liver IL‐6 showed decreased mRNA in FC‐fed mice. The renal 1,25‐dihydroxyvitamin D (1,25D) anabolic enzyme Cyp27b1 had higher mRNA and the catabolic Cyp24a1 showed lower mRNA in FC‐fed mice. Finally, mice with loss of FGF23 had higher bone cortical porosity, whereas Raman spectroscopy showed no changes in matrix mineral parameters. Thus, FC‐ and FGF23‐dependent and ‐independent actions were identified in CKD; loss of FGF23 was associated with higher serum Pi and BUN, demonstrating that FGF23 was protective of mineral metabolism. In contrast, FC maintained serum iron and corrected inflammation mediators, potentially providing ancillary benefit.
Chronic kidney disease (CKD) affects 10% of the world population and results in many patient complications, including iron deficiency and hyperphosphatemia, both potent stimulators of the phosphaturic hormone FGF23. An iron‐containing phosphate binder, ferric citrate (FC), was developed to alleviate these manifestations, however, the impact of FC on FGF23‐ and iron‐mediated effects in CKD are not completely understood. This study provides novel insight into the FGF23‐ and iron‐mediated effects in CKD. We demonstrate that FGF23 is necessary to control phosphate and disease progression (monitored by BUN) in CKD. This study also supports that FC may improve 1,25D metabolism independent of FGF23 and lower markers of inflammation due to iron repletion. Therefore, FC may provide ancillary benefits which could lead to improved CKD patient outcomes. Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD remain unclear. To this end, iron and Pi metabolism were tested in a mouse model of CKD (0.2% adenine) ± 0.5% FC for 6 weeks, with and without osteocyte deletion of Fgf23 (flox‐Fgf23/Dmp1‐Cre). Intact FGF23 (iFGF23) increased in all CKD mice but was lower in Cre+ mice with or without FC, thus the Dmp1‐Cre effectively reduced FGF23. Cre+ mice fed AD‐only had higher serum Pi than Cre− pre‐ and post‐diet, and the Cre+ mice had higher BUN regardless of FC treatment. Total serum iron was higher in all mice receiving FC, and liver Tfrc, Bmp6, and hepcidin mRNAs were increased regardless of genotype; liver IL‐6 showed decreased mRNA in FC‐fed mice. The renal 1,25‐dihydroxyvitamin D (1,25D) anabolic enzyme Cyp27b1 had higher mRNA and the catabolic Cyp24a1 showed lower mRNA in FC‐fed mice. Finally, mice with loss of FGF23 had higher bone cortical porosity, whereas Raman spectroscopy showed no changes in matrix mineral parameters. Thus, FC‐ and FGF23‐dependent and ‐independent actions were identified in CKD; loss of FGF23 was associated with higher serum Pi and BUN, demonstrating that FGF23 was protective of mineral metabolism. In contrast, FC maintained serum iron and corrected inflammation mediators, potentially providing ancillary benefit. Chronic kidney disease (CKD) affects 10% of the world population and results in many patient complications, including iron deficiency and hyperphosphatemia, both potent stimulators of the phosphaturic hormone FGF23. An iron‐containing phosphate binder, ferric citrate (FC), was developed to alleviate these manifestations, however, the impact of FC on FGF23‐ and iron‐mediated effects in CKD are not completely understood. This study provides novel insight into the FGF23‐ and iron‐mediated effects in CKD. We demonstrate that FGF23 is necessary to control phosphate and disease progression (monitored by BUN) in CKD. This study also supports that FC may improve 1,25D metabolism independent of FGF23 and lower markers of inflammation due to iron repletion. Therefore, FC may provide ancillary benefits which could lead to improved CKD patient outcomes. Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD remain unclear. To this end, iron and Pi metabolism were tested in a mouse model of CKD (0.2% adenine) ± 0.5% FC for 6 weeks, with and without osteocyte deletion of Fgf23 (flox‐Fgf23/Dmp1‐Cre). Intact FGF23 (iFGF23) increased in all CKD mice but was lower in Cre+ mice with or without FC, thus the Dmp1‐Cre effectively reduced FGF23. Cre+ mice fed AD‐only had higher serum Pi than Cre− pre‐ and post‐diet, and the Cre+ mice had higher BUN regardless of FC treatment. Total serum iron was higher in all mice receiving FC, and liver Tfrc, Bmp6, and hepcidin mRNAs were increased regardless of genotype; liver IL‐6 showed decreased mRNA in FC‐fed mice. The renal 1,25‐dihydroxyvitamin D (1,25D) anabolic enzyme Cyp27b1 had higher mRNA and the catabolic Cyp24a1 showed lower mRNA in FC‐fed mice. Finally, mice with loss of FGF23 had higher bone cortical porosity, whereas Raman spectroscopy showed no changes in matrix mineral parameters. Thus, FC‐ and FGF23‐dependent and ‐independent actions were identified in CKD; loss of FGF23 was associated with higher serum Pi and BUN, demonstrating that FGF23 was protective of mineral metabolism. In contrast, FC maintained serum iron and corrected inflammation mediators, potentially providing ancillary benefit. Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis-dependent CKD, and for iron deficiency anemia (IDA) in non-dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD remain unclear. To this end, iron and Pi metabolism were tested in a mouse model of CKD (0.2% adenine) ± 0.5% FC for 6 weeks, with and without osteocyte deletion of Fgf23 (flox-Fgf23/Dmp1-Cre). Intact FGF23 (iFGF23) increased in all CKD mice but was lower in Cre mice with or without FC, thus the Dmp1-Cre effectively reduced FGF23. Cre mice fed AD-only had higher serum Pi than Cre pre- and post-diet, and the Cre mice had higher BUN regardless of FC treatment. Total serum iron was higher in all mice receiving FC, and liver Tfrc, Bmp6, and hepcidin mRNAs were increased regardless of genotype; liver IL-6 showed decreased mRNA in FC-fed mice. The renal 1,25-dihydroxyvitamin D (1,25D) anabolic enzyme Cyp27b1 had higher mRNA and the catabolic Cyp24a1 showed lower mRNA in FC-fed mice. Finally, mice with loss of FGF23 had higher bone cortical porosity, whereas Raman spectroscopy showed no changes in matrix mineral parameters. Thus, FC- and FGF23-dependent and -independent actions were identified in CKD; loss of FGF23 was associated with higher serum Pi and BUN, demonstrating that FGF23 was protective of mineral metabolism. In contrast, FC maintained serum iron and corrected inflammation mediators, potentially providing ancillary benefit. Abstract Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD remain unclear. To this end, iron and Pi metabolism were tested in a mouse model of CKD (0.2% adenine) ± 0.5% FC for 6 weeks, with and without osteocyte deletion of Fgf23 (flox‐Fgf23/Dmp1‐Cre). Intact FGF23 (iFGF23) increased in all CKD mice but was lower in Cre+ mice with or without FC, thus the Dmp1‐Cre effectively reduced FGF23. Cre+ mice fed AD‐only had higher serum Pi than Cre− pre‐ and post‐diet, and the Cre+ mice had higher BUN regardless of FC treatment. Total serum iron was higher in all mice receiving FC, and liver Tfrc, Bmp6, and hepcidin mRNAs were increased regardless of genotype; liver IL‐6 showed decreased mRNA in FC‐fed mice. The renal 1,25‐dihydroxyvitamin D (1,25D) anabolic enzyme Cyp27b1 had higher mRNA and the catabolic Cyp24a1 showed lower mRNA in FC‐fed mice. Finally, mice with loss of FGF23 had higher bone cortical porosity, whereas Raman spectroscopy showed no changes in matrix mineral parameters. Thus, FC‐ and FGF23‐dependent and ‐independent actions were identified in CKD; loss of FGF23 was associated with higher serum Pi and BUN, demonstrating that FGF23 was protective of mineral metabolism. In contrast, FC maintained serum iron and corrected inflammation mediators, potentially providing ancillary benefit. |
Author | Ni, Pu Allen, Matthew R. Agoro, Rafiou Clinkenbeard, Erica L. Damrath, John G. Hum, Julia M. Wallace, Joseph M. Swallow, Elizabeth A. Noonan, Megan L. White, Kenneth E. Liesen, Michael P. |
AuthorAffiliation | 2 Department of Physiology Marian University Indianapolis Indiana USA 4 Department of Biomedical Engineering Indiana University‐Purdue University at Indianapolis Indianapolis Indiana USA 6 Department of Medicine Division of Nephrology Indiana University School of Medicine Indianapolis Indiana USA 1 Department of Medical & Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USA 5 Department of Anatomy, Cell Biology, and Physiology Indiana University School of Medicine Indianapolis Indiana USA 3 Purdue University Weldon School of Biomedical Engineering West Lafayette Indiana USA |
AuthorAffiliation_xml | – name: 5 Department of Anatomy, Cell Biology, and Physiology Indiana University School of Medicine Indianapolis Indiana USA – name: 4 Department of Biomedical Engineering Indiana University‐Purdue University at Indianapolis Indianapolis Indiana USA – name: 2 Department of Physiology Marian University Indianapolis Indiana USA – name: 1 Department of Medical & Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USA – name: 3 Purdue University Weldon School of Biomedical Engineering West Lafayette Indiana USA – name: 6 Department of Medicine Division of Nephrology Indiana University School of Medicine Indianapolis Indiana USA |
Author_xml | – sequence: 1 givenname: Michael P. surname: Liesen fullname: Liesen, Michael P. organization: Marian University – sequence: 2 givenname: Megan L. orcidid: 0000-0002-1763-1867 surname: Noonan fullname: Noonan, Megan L. organization: Indiana University School of Medicine – sequence: 3 givenname: Pu surname: Ni fullname: Ni, Pu organization: Indiana University School of Medicine – sequence: 4 givenname: Rafiou surname: Agoro fullname: Agoro, Rafiou organization: Indiana University School of Medicine – sequence: 5 givenname: Julia M. surname: Hum fullname: Hum, Julia M. organization: Marian University – sequence: 6 givenname: Erica L. surname: Clinkenbeard fullname: Clinkenbeard, Erica L. organization: Indiana University School of Medicine – sequence: 7 givenname: John G. surname: Damrath fullname: Damrath, John G. organization: Purdue University Weldon School of Biomedical Engineering – sequence: 8 givenname: Joseph M. surname: Wallace fullname: Wallace, Joseph M. organization: Indiana University‐Purdue University at Indianapolis – sequence: 9 givenname: Elizabeth A. surname: Swallow fullname: Swallow, Elizabeth A. organization: Indiana University School of Medicine – sequence: 10 givenname: Matthew R. surname: Allen fullname: Allen, Matthew R. organization: Indiana University School of Medicine – sequence: 11 givenname: Kenneth E. orcidid: 0000-0003-1244-5261 surname: White fullname: White, Kenneth E. email: kenewhit@iu.edu organization: Indiana University School of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35656701$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kk9rFDEUwINYbK09eZeAF0G25n9mLoKsbltaUFBBTyGTvJnNMjtZMzPKevIj-Bn7SZrdqcV68JK8JL_8eHl5j9HDLnaA0FNKTqkoqHi1WW7ZKZWc6AfoiBFJZwXVXw7RSd-vCCGUcF4S8Qgdcqmk0oQeoeYjNAkaO4SuwcMSMNQ1uKHHscY1pBQcdmFIdoDrX7_X4EOOPA4pdngcQht-5ps5tp3Hi7MF4zjkBV7HsYc8emh3ovnl2yfooLZtDye38zH6vHj3aX4-u3p_djF_czVzQlE9YwBeVIKVSitegJPEEVYJXdWKW5rTZ7RW0leaFNyD1HVRakXBZ4oXWhf8GF1MXh_tymxSWNu0NdEGs9-IqTE2DcG1YHypKS_BlU4WwllROkGIZYRLLb2ULrteT67NWOWnO-hyIdp70vsnXViaJn43Jc3JE5oFL24FKX4boR_MOvQO2tZ2kCtkmNKcS6kpy-jzf9BVHFOXS7WjlCSF5GWmXk6US7HvE9R3yVBi9j1gdj1g9j2Q6Wd_53_H_vn9DLAJ-BFa2P7PZT6cf2WT9QagX77q |
CitedBy_id | crossref_primary_10_1007_s00223_023_01092_1 |
Cites_doi | 10.1681/ASN.2018101016 10.1073/pnas.1110905108 10.1371/journal.pone.0188712 10.1681/ASN.2009121311 10.1093/ndt/gfw376 10.1007/s40265‐019‐01125‐w 10.14814/phy2.14434 10.1007/s00424‐018‐2171‐7 10.1001/jama.2019.22450 10.1002/jbmr.2049 10.1002/jbmr.4272 10.1371/journal.pone.0084943 10.1038/81664 10.1002/jat.727 10.1002/jbmr.3878 10.1007/s11914‐017‐0366‐z 10.1159/000496492 10.1096/fj.201700667R 10.3390/ijms20174195 10.1210/en.2003-1768 10.3324/haematol.2019.237040 10.1681/ASN.V133734 10.1172/jci.insight.123817 10.1002/jbmr.1923 10.1053/j.ajkd.2009.12.030 10.1002/jbmr.2792 10.1007/s40610‐016‐0035‐5 10.1001/jama.2011.826 10.1159/000489964 10.1038/s41598‐019‐45335‐4 10.1038/s41598‐018‐25439‐z 10.3324/haematol.2017.167882 10.1677/JOE‐10‐0181 10.1210/jc.2011‐1239 10.1194/jlr.R031534 10.1152/physrev.00002.2011 10.1007/s40610‐019‐0110‐9 10.1016/j.kint.2019.07.026 10.1002/jbmr.1916 10.1681/ASN.2014020212 10.1074/jbc.M408903200 10.1172/JCI46122 10.1053/j.ajkd.2014.10.014 |
ContentType | Journal Article |
Copyright | 2022 The Authors. published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society. 2022 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society. 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2022 The Authors. published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society. – notice: 2022 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society. – notice: 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QP 7T5 7TK 7X7 7XB 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M7P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.14814/phy2.15307 |
DatabaseName | Wiley Online Library Open Access Wiley Online Library Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Immunology Abstracts Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley-Blackwell Open Access Collection url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
DocumentTitleAlternate | LIESEN et al |
EISSN | 2051-817X |
EndPage | n/a |
ExternalDocumentID | oai_doaj_org_article_d97139ec9c584ca49c400a203575d55c 10_14814_phy2_15307 35656701 PHY215307 |
Genre | article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: National Institute of Diabetes and Digestive and Kidney Diseases funderid: F30DK121399; F31DK122679 – fundername: Akebia Therapeutics – fundername: NIDDK NIH HHS grantid: F30DK121399 – fundername: NIDDK NIH HHS grantid: F31DK122679 – fundername: ; – fundername: ; grantid: F30DK121399; F31DK122679 |
GroupedDBID | 0R~ 1OC 24P 53G 5VS 7X7 8-1 8FE 8FH 8FI 8FJ AAFWJ AAHHS AAZKR ABDBF ABUWG ACCFJ ACXQS ADBBV ADKYN ADRAZ ADZMN AEEZP AEQDE AFKRA AFPKN AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU DIK EBS EJD FYUFA GODZA GROUPED_DOAJ HCIFZ HMCUK HYE IAO IHR INH KQ8 LK8 M48 M7P M~E OK1 PIMPY PQQKQ PROAC RAP RHI RPM UKHRP WIN CGR CUY CVF ECM EIF ITC NPM AAYXX CITATION 3V. 7QP 7T5 7TK 7XB 8FK AZQEC DWQXO GNUQQ H94 K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c4617-2eed4b42967638ec50c02b47bf63a133921f65db7083de57f89761edc02387783 |
IEDL.DBID | RPM |
IngestDate | Fri Oct 04 13:14:19 EDT 2024 Tue Sep 17 20:55:14 EDT 2024 Sat Oct 05 06:01:00 EDT 2024 Thu Oct 10 19:43:19 EDT 2024 Thu Sep 26 18:59:27 EDT 2024 Wed Oct 16 00:41:07 EDT 2024 Sat Aug 24 01:03:14 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | GF23 kidney klotho iron ferric citrate CKD |
Language | English |
License | Attribution 2022 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4617-2eed4b42967638ec50c02b47bf63a133921f65db7083de57f89761edc02387783 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-1244-5261 0000-0002-1763-1867 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163801/ |
PMID | 35656701 |
PQID | 2676508539 |
PQPubID | 2034607 |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_d97139ec9c584ca49c400a203575d55c pubmedcentral_primary_oai_pubmedcentral_nih_gov_9163801 proquest_miscellaneous_2673355712 proquest_journals_2676508539 crossref_primary_10_14814_phy2_15307 pubmed_primary_35656701 wiley_primary_10_14814_phy2_15307_PHY215307 |
PublicationCentury | 2000 |
PublicationDate | June 2022 |
PublicationDateYYYYMMDD | 2022-06-01 |
PublicationDate_xml | – month: 06 year: 2022 text: June 2022 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Oxford – name: Hoboken |
PublicationTitle | Physiological reports |
PublicationTitleAlternate | Physiol Rep |
PublicationYear | 2022 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
References | 2004; 145 2010; 55 2019; 9 2019; 4 2013; 28 2019; 5 2019; 30 2010; 207 2019; 96 2000; 26 2021; 106 2019; 79 2002; 13 2016; 31 2011; 96 2020; 35 2014; 29 2020; 323 2019; 142 2018; 47 2001; 21 2020; 8 2021; 36 2015; 26 2012; 92 2005; 280 2018; 8 2011; 108 2016; 2 2018; 470 2011; 305 2019; 20 2017; 15 2017; 32 2015; 65 2017; 12 2011; 22 2014; 9 2018; 32 2017; 102 2014; 55 2011; 121 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_44_1 e_1_2_8_41_1 e_1_2_8_40_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_16_1 e_1_2_8_37_1 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_30_1 |
References_xml | – volume: 106 start-page: 391 year: 2021 end-page: 403 article-title: C‐FGF23 peptide alleviates hypoferremia during acute inflammation publication-title: Haematologica – volume: 323 start-page: 432 year: 2020 end-page: 443 article-title: Effects of iron isomaltoside vs. ferric carboxymaltose on hypophosphatemia in iron‐deficiency anemia: Two randomized clinical trials publication-title: JAMA – volume: 26 start-page: 493 year: 2015 end-page: 503 article-title: Ferric citrate controls phosphorus and delivers iron in patients on dialysis publication-title: Journal of the American Society of Nephrology – volume: 92 start-page: 131 year: 2012 end-page: 155 article-title: Regulation and function of the FGF23/Klotho endocrine pathways publication-title: Physiological Reviews – volume: 470 start-page: 1569 year: 2018 end-page: 1582 article-title: Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men publication-title: Pflügers Archiv ‐ European Journal of Physiology – volume: 96 start-page: 1346 year: 2019 end-page: 1358 article-title: Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease publication-title: Kidney International – volume: 96 start-page: 3541 year: 2011 end-page: 3549 article-title: Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 305 start-page: 2432 year: 2011 article-title: Fibroblast growth factor 23 and risks of mortality and end‐stage renal disease in patients with chronic kidney disease publication-title: JAMA – volume: 102 start-page: e427 year: 2017 end-page: e430 article-title: Erythropoietin stimulates murine and human fibroblast growth factor‐23, revealing novel roles for bone and bone marrow publication-title: Haematologica – volume: 20 start-page: 4195 issue: 17 year: 2019 article-title: The role of fibroblast growth factor 23 in inflammation and anemia publication-title: International Journal of Molecular Sciences – volume: 9 year: 2014 article-title: Prevalence of anemia in chronic kidney disease in the United States publication-title: PLoS One – volume: 8 year: 2020 article-title: Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD) publication-title: Physiological Reports – volume: 47 start-page: 406 year: 2018 end-page: 414 article-title: Ferric citrate decreases fibroblast growth factor 23 and improves erythropoietin responsiveness in hemodialysis patients publication-title: American Journal of Nephrology – volume: 280 start-page: 2543 year: 2005 end-page: 2549 article-title: Circulating FGF‐23 is regulated by 1alpha,25‐dihydroxyvitamin D3 and phosphorus in vivo publication-title: Journal of Biological Chemistry – volume: 26 start-page: 345 year: 2000 end-page: 348 article-title: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 publication-title: Nature Genetics – volume: 28 start-page: 1793 year: 2013 end-page: 1803 article-title: Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women publication-title: Journal of Bone and Mineral Research – volume: 21 start-page: 15 year: 2001 end-page: 23 article-title: A good practice guide to the administration of substances and removal of blood, including routes and volumes publication-title: Journal of Applied Toxicology – volume: 55 start-page: 726 year: 2010 end-page: 741 article-title: Molecular mechanisms of hepcidin regulation: Implications for the Anemia of CKD publication-title: American Journal of Kidney Diseases – volume: 142 start-page: 44 year: 2019 end-page: 50 article-title: Iron deficiency anemia in chronic kidney disease publication-title: Acta Haematologica – volume: 207 start-page: 67 year: 2010 end-page: 75 article-title: Altered renal FGF23‐mediated activity involving MAPK and Wnt: Effects of the Hyp mutation publication-title: Journal of Endocrinology – volume: 4 issue: 4 year: 2019 article-title: Increased FGF23 protects against detrimental cardio‐renal consequences during elevated blood phosphate in CKD publication-title: JCI Insight – volume: 65 start-page: 728 year: 2015 end-page: 736 article-title: A 12‐week, double‐blind, placebo‐controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3–5 publication-title: American Journal of Kidney Diseases – volume: 55 start-page: 13 year: 2014 end-page: 31 article-title: Cytochrome P450‐mediated metabolism of vitamin D publication-title: Journal of Lipid Research – volume: 28 start-page: 1811 year: 2013 end-page: 1820 article-title: Rapid cortical bone loss in patients with chronic kidney disease publication-title: Journal of Bone and Mineral Research – volume: 30 start-page: 1495 issue: 8 year: 2019 end-page: 1504 article-title: A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD publication-title: Journal of the American Society of Nephrology – volume: 108 start-page: E1146 year: 2011 end-page: E1155 article-title: Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor‐23 (Fgf23) knock‐in mice publication-title: Proceedings of the National Academy of Sciences – volume: 13 start-page: 734 year: 2002 end-page: 744 article-title: Iron administration and clinical outcomes in hemodialysis patients publication-title: Journal of the American Society of Nephrology – volume: 32 start-page: 960 year: 2017 end-page: 968 article-title: Spleen contributes significantly to increased circulating levels of fibroblast growth factor 23 in response to lipopolysaccharide‐induced inflammation publication-title: Nephrology, Dialysis, Transplantation – volume: 79 start-page: 957 year: 2019 end-page: 968 article-title: Mechanism of action and clinical attributes of Auryxia® (Ferric Citrate) publication-title: Drugs – volume: 36 start-page: 1117 issue: 6 year: 2021 end-page: 1130 article-title: The HIF‐PHI BAY 85–3934 (Molidustat) improves anemia and is associated with reduced levels of circulating FGF23 in a CKD mouse model publication-title: Journal of Bone and Mineral Research – volume: 145 start-page: 3087 year: 2004 end-page: 3094 article-title: Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis publication-title: Endocrinology – volume: 121 start-page: 4393 year: 2011 end-page: 4408 article-title: FGF23 induces left ventricular hypertrophy publication-title: Journal of Clinical Investigation – volume: 15 start-page: 207 year: 2017 end-page: 213 article-title: Bone quality in chronic kidney disease: Definitions and diagnostics publication-title: Current Osteoporosis Reports – volume: 9 start-page: 8877 year: 2019 article-title: Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study publication-title: Scientific Reports – volume: 29 start-page: 361 issue: 2 year: 2014 end-page: 369 article-title: Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice publication-title: Journal of Bone and Mineral Research – volume: 22 start-page: 124 year: 2011 end-page: 136 article-title: Klotho deficiency causes vascular calcification in chronic kidney disease publication-title: Journal of the American Society of Nephrology – volume: 12 year: 2017 article-title: Safety and efficacy of ferric citrate in patients with nondialysis‐dependent chronic kidney disease publication-title: PLoS One – volume: 35 start-page: 231 year: 2020 end-page: 238 article-title: Oral iron replacement normalizes fibroblast growth factor 23 in iron‐deficient patients with autosomal dominant hypophosphatemic rickets publication-title: Journal of Bone and Mineral Research – volume: 32 start-page: 3752 year: 2018 end-page: 3764 article-title: Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia publication-title: The FASEB Journal – volume: 31 start-page: 1247 year: 2016 end-page: 1257 article-title: Conditional deletion of MurineFgf23: Interruption of the normal skeletal responses to phosphate challenge and rescue of genetic hypophosphatemia publication-title: Journal of Bone and Mineral Research – volume: 2 start-page: 62 issue: 1 year: 2016 end-page: 71 article-title: Systemic control of bone homeostasis by FGF23 signaling publication-title: Current Molecular Biology Reports – volume: 5 start-page: 8 year: 2019 end-page: 17 article-title: Regulation of fibroblast growth factor 23 by iron, EPO, and HIF publication-title: Current Molecular Biology Reports – volume: 8 start-page: 7294 year: 2018 article-title: Circulating fibroblast growth factor‐23 levels are associated with an increased risk of anemia development in patients with nondialysis chronic kidney disease publication-title: Scientific Reports – ident: e_1_2_8_6_1 doi: 10.1681/ASN.2018101016 – ident: e_1_2_8_18_1 doi: 10.1073/pnas.1110905108 – ident: e_1_2_8_8_1 doi: 10.1371/journal.pone.0188712 – ident: e_1_2_8_24_1 doi: 10.1681/ASN.2009121311 – ident: e_1_2_8_5_1 doi: 10.1093/ndt/gfw376 – ident: e_1_2_8_23_1 doi: 10.1007/s40265‐019‐01125‐w – ident: e_1_2_8_36_1 doi: 10.14814/phy2.14434 – ident: e_1_2_8_15_1 doi: 10.1007/s00424‐018‐2171‐7 – ident: e_1_2_8_43_1 doi: 10.1001/jama.2019.22450 – ident: e_1_2_8_10_1 doi: 10.1002/jbmr.2049 – ident: e_1_2_8_37_1 doi: 10.1002/jbmr.4272 – ident: e_1_2_8_39_1 doi: 10.1371/journal.pone.0084943 – ident: e_1_2_8_41_1 doi: 10.1038/81664 – ident: e_1_2_8_16_1 doi: 10.1002/jat.727 – ident: e_1_2_8_25_1 doi: 10.1002/jbmr.3878 – ident: e_1_2_8_33_1 doi: 10.1007/s11914‐017‐0366‐z – ident: e_1_2_8_22_1 doi: 10.1159/000496492 – ident: e_1_2_8_2_1 doi: 10.1096/fj.201700667R – ident: e_1_2_8_14_1 doi: 10.3390/ijms20174195 – ident: e_1_2_8_29_1 doi: 10.1210/en.2003-1768 – ident: e_1_2_8_3_1 doi: 10.3324/haematol.2019.237040 – ident: e_1_2_8_20_1 doi: 10.1681/ASN.V133734 – ident: e_1_2_8_12_1 doi: 10.1172/jci.insight.123817 – ident: e_1_2_8_42_1 doi: 10.1002/jbmr.1923 – ident: e_1_2_8_4_1 doi: 10.1053/j.ajkd.2009.12.030 – ident: e_1_2_8_9_1 doi: 10.1002/jbmr.2792 – ident: e_1_2_8_13_1 doi: 10.1007/s40610‐016‐0035‐5 – ident: e_1_2_8_27_1 doi: 10.1001/jama.2011.826 – ident: e_1_2_8_32_1 doi: 10.1159/000489964 – ident: e_1_2_8_44_1 doi: 10.1038/s41598‐019‐45335‐4 – ident: e_1_2_8_34_1 doi: 10.1038/s41598‐018‐25439‐z – ident: e_1_2_8_11_1 doi: 10.3324/haematol.2017.167882 – ident: e_1_2_8_17_1 doi: 10.1677/JOE‐10‐0181 – ident: e_1_2_8_26_1 doi: 10.1210/jc.2011‐1239 – ident: e_1_2_8_28_1 doi: 10.1194/jlr.R031534 – ident: e_1_2_8_31_1 doi: 10.1152/physrev.00002.2011 – ident: e_1_2_8_40_1 doi: 10.1007/s40610‐019‐0110‐9 – ident: e_1_2_8_21_1 doi: 10.1016/j.kint.2019.07.026 – ident: e_1_2_8_35_1 doi: 10.1002/jbmr.1916 – ident: e_1_2_8_30_1 doi: 10.1681/ASN.2014020212 – ident: e_1_2_8_38_1 doi: 10.1074/jbc.M408903200 – ident: e_1_2_8_19_1 doi: 10.1172/JCI46122 – ident: e_1_2_8_7_1 doi: 10.1053/j.ajkd.2014.10.014 |
SSID | ssj0001033904 |
Score | 2.2728415 |
Snippet | Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron... Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis-dependent CKD, and for iron... Abstract Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for... |
SourceID | doaj pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | e15307 |
SubjectTerms | Anemia Animals Bone morphogenetic protein 6 Citric Acid CKD Clinical outcomes Cortical bone Dialysis Diet Disease Disease Models, Animal Electrolytes Ferric citrate Ferric Compounds Fibroblast Growth Factor-23 Fibroblast Growth Factors - metabolism Gene expression Genotype & phenotype Genotypes GF23 Hemodialysis Hepcidin Humans Interleukin 6 Iron Iron - metabolism Iron deficiency kidney Kidney diseases klotho Liver Metabolism Mice Minerals mRNA Nutrient deficiency Original Patients Physiology Porosity Raman spectroscopy Renal Insufficiency, Chronic - metabolism Rickets RNA, Messenger - metabolism Vitamin D |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQtDwCBRmp4oJCEz_i-FgKy6pVKySoVE6W4zjtSm2KSjlw60_ob-wv6TdOutoVVblw2914V5N5ZL6Z9XxmbEMUtiljVSLS6AizUPkcaaTKRett4Wsg_NQa2Nuvpgdq51AfLhz1RXvCBnrgQXGbrUUZZWOwAakyeGUDvM6LQgJntFqH9PQt9UIxlborhUQxr8aBPFWXahNSiw-Ibzo4diEFJab-u-Dl37skF9FrSj-Tx-zRiBv51iDvE_Yg9qtsbatHzXz6h7_jaSdnapGvsaNvEVU0UWf0RxwAj4-bNvhZxztiYgw8zBIr7fXlVRodAezkNO_G4YYn42Qm933LJ18mQvIZ3nDqEUSeTs6hH9re_fSUHUw-f9-e5uOBCnlQQCq5QEJUDTJQhadKHYMuQiEaZZqukh7FqhVlV-m2McBlbdSmqwFWSmiAErsxtXzGVvqzPr5g3Lad8sZiARHONaaORdUCvcWoJTHGZGzjVsfu58Cb4ajeIFM4MoVLpsjYR9L_fAmRXacP4AJudAH3LxfI2Pqt9dwYgb-cwD0CfGppM_Z2fhmxQ3-I-D5CZ7RGAm-ZEuI-H4w9l0QS0jVFmTGz5AZLoi5f6WfHiZ_bEsalb75PDnPf_buv0x8ivXr5PzTxij0UNJ6RukTrbOXi_Hd8DdB00bxJ8XEDP0YRWg priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NTtwwEB5RuPRStaU_aWllJNRLlZLYThyfEFC2K6oi1BaJnizHdpaVIEuBHnrrI_CMfZLOeL0LqyJum40TOfPj-WbsmQHY4IVuy1CXqGnUwszVNkczUufcW13YBhF-DA18OaiHR3L_uDpOAbfLdKxytibGhdpPHMXIN3mtCExUQm-d_8ypaxTtrqYWGg9ghZeStmlXdvYODr_eRFkKgU69TIl5sinlJs6ef0A9pwayt0xRrNh_F8z8_7TkbRQbzdDgMTxK-JFtTxn-BJZC_xRWt3v0nc9-s3csnuiMofJVGH0L6E1TCY1-xBDosXR4g0061lFFRsfcOFan_fvnOqaQIPxklPfGUBxPU4Yms71ng08DLtgYLxjFCgKLHXToRbufPz6Do8He991hnhor5E4iYsk5GkbZoiVCmoomuKpwBW-lartaWHRaNS-7uvKtQnzmQ6W6BkFLiRQgA69UI57Dcj_pw0tg2nfSKo0DqPBcq5pQ1B5RXAiVoMoxGWzMaGzOp_UzDPkdxApDrDCRFRnsEP3nQ6jodfxjcjEySYeM1-hR6-C0Q9TkrNQOFyDLC4GQ01eVy2Btxj2TNPHS3MhNBuvz26hDtDFi-4A0ozECcZcqcbovpsyez0QQ4lVFmYFaEIOFqS7e6ccnsU63JqxLT76PAnPf95vD4Q8ef726_yNew0NOCRgxDrQGy1cXv8IbhEVX7dsk-_8A8VcK7g priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaq9sIFUcojtCAjVVxQSmI7cXxAVVtYVqAiJFipnCzHcbYrlSwsRaK3_oT-Rn5Jv_FmVyxUSNzycCJ7HplvJp4ZxnZFZuo8lDk0jVqY-dKlMCNlKhpnMlcB4cfQwPH7cjhSb0-KkzW2aMbZE_D7ja4d9ZMazc72fn672IfCvySFV1WuXmBCYg-qS1nlG0JJRaJ-3OP8GGzJJHx71efn_fHMikWKhftvQpt_b5r8HcxGazS4w273MJIfzPm-ydZCd5dtHXRwob9c8Gc8buyMEfMtNv4Y4FRTJY1uzIH3eL-Hg09b3lJhRs_9JBap_XV5FTNJgEI5pb9xSOVZn6jJXdfwwZuBkHyCE04hg8BjIx160dG7V_fYaPD609Ew7fsrpF4BuKQC9lHVMEglPjJV8EXmM1ErXbeldPBdjcjbsmhqDZjWhEK3FbBLDgqQnde6kvfZejftwkPGTdMqpw0GUP25WlchKxuAuRAKSQVkEra7oLH9Oi-jYcn9IFZYYoWNrEjYIdF_OYRqX8cL09nY9qpkGwPH2gRvPMCTd8p4fIecyCSQZ1MUPmE7C-7ZhTxZgTUCixbSJOzp8jZUif6PuC6AZjRGAn7pHNN9MGf2ciaSgK_O8oTpFTFYmerqnW5yGst1G4K89OTzKDD_Wr_9MPws4tGj_xq9zW4JSsuI0aEdtn4--xEeAyyd10-iIlwDzGMPhw priority: 102 providerName: Scholars Portal – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3BbtQwELVQuXCpWhba0IKMVHFBoYntxPGxLCwrEKgSVGpPluM425VKtmrLoTc-gW_kS3jjpFtWrZC4bTZ25Hg8njcTzxvG9kRm6jyUOTSNSpj50qUwI2UqGmcyVwHhx9DA5y_l9Eh9PC6Oh7M5lAvT80MsA26kGXG_JgV3dV-FRFW5otK0p9fiDRSWcskfAthUtKiFOrwNsWQSHr0asvKo1_5tnxU7FOn678OYd49K_g1how2abLD1ATzyg17am-xB6B6z0UEHx_n7NX_F43HOGCcfsdnXAFea-DO6GQfK48PJDb5oeUt0jJ77eaSm_f3zV8wfAfbklPTGsRbPhvRM7rqGTz5MhORzXHAKFAQey-fQg8af3j1hR5P338bTdKiqkHoFuJIKWEVVwwyV2Fqq4IvMZ6JWum5L6eCxGpG3ZdHUGuCsCYVuKyCWHDNA1l3rSj5la92iC9uMm6ZVThs0INa5WlchKxtAuBAKSbQxCdu7mWN73pNnWHI6SBSWRGGjKBL2luZ_2YQYr-Mfi4uZHRTINgbutAneeEAm75Tx2H2cyCTwZlMUPmG7N9KzgxpeWoF3BAItpEnYy-VtKBB9FXFdwJxRGwnQpXMMd6sX9nIkkuCuzvKE6ZVlsDLU1Tvd_DSSdBsCutTzdVww_3p_ezg9EfHXs_9qvcMeCUrGiDGhXbZ2dfEjPAdEuqpfREX4A82bCtg priority: 102 providerName: Wiley-Blackwell |
Title | Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD |
URI | https://onlinelibrary.wiley.com/doi/abs/10.14814%2Fphy2.15307 https://www.ncbi.nlm.nih.gov/pubmed/35656701 https://www.proquest.com/docview/2676508539 https://search.proquest.com/docview/2673355712 https://pubmed.ncbi.nlm.nih.gov/PMC9163801 https://doaj.org/article/d97139ec9c584ca49c400a203575d55c |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB415YyA8jAq0SJVXJATex9e77ENDVFRqgioFE4re70OkRqnKuXQW38Cv5FfwszGjhpRceBiOfEqGe_MeL4ZzwPgiCemTH2WoqbRCDOXFTGakSzmVWGSIkeEH0ID0_NsciHP5mq-B6qrhQlJ-65cDprL1aBZfg-5lVcrN-zyxIaz6cgQiEjSYQ96Woh7LnoIrCQC_XjZ1uLJPJVDJJgPULUTGrknCMLodghMZ4hCv_6HQObfuZL3MWwwQuMn8LhFj-x4Q-VT2PPNMzg4btBzXt2ydyzkc4ZA-QEsvnj0pamBRrNgCPNYm7rB1jWrqR-jY24ZetP-vvsVCkgQfDKqemMojJdtfSYrmoqNP465YEv8wChS4FmYn0M_NPr04TlcjE-_jiZxO1YhdhLxSszRLMoS7VCGz5bcO5W4hJdSl3UmCnRZDU_rTFWlRnRWeaXrHCFLijtA5l3rXLyA_Wbd-FfATFXLQhtcQG3nSp37JKsQw3mvBPWNieCo22N7temeYcnrIK5Y4ooNXInghPZ_u4RaXocv1tcL2zLeVgb9aeOdcYiZXCGNw8dPwROBgLNSykVw2HHPtnr4w3K8R4SgSpgI3m4vowbRa5Gi8bhntEYg6tIpkvtyw-wtJZ2wRKB3xGCH1N0rKLShS3crpBG8DwLzr_u3s8k3Hs5e__f_HML-zfVP_wYh0k3Zhx6XMzzque7Do5PT89nnfgg34HEq835QmT-wxBWF |
link.rule.ids | 230,315,733,786,790,870,891,2115,11589,12083,21416,24346,27955,27956,31752,31753,33777,33778,43343,43838,46085,46509,50847,50956,53825,53827,74100,74657 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BOcClAsojUMBIFRcUmthOHJ9QKSwLfQiJVlpOlmM7y0olW9py4MZP4Df2l3TG6912BeotDydy5uH5ZuKZAdjghW7LUJeoadTCzNU2RzNS59xbXdgGEX4MDezt18ND-XlUjVLA7TRtq5yviXGh9lNHMfJNXisCE5XQb49_5tQ1iv6uphYaN-GWFEKSnKuRuoyxFAJdepnS8mRTyk2cO3-DWk7tY68Yoliv_38g89-9klcxbDRCg7uwmtAj25qx-x7cCP19WNvq0XP-8Zu9YnE_ZwyUr8H4a0Bfmgpo9GOGMI-lrRts2rGO6jE65iaxNu35n78xgQTBJ6OsN4bCeJTyM5ntPRt8HHDBJnjCKFIQWOyfQy_a3nn_AA4HHw62h3lqq5A7iXgl52gWZYt2CCkqmuCqwhW8lartamHRZdW87OrKtwrRmQ-V6hqELCVSgMy7Uo14CCv9tA-PgWnfSas0DqCyc61qQlF7xHAhVILqxmSwMaexOZ5VzzDkdRArDLHCRFZk8I7ovxhCJa_jhenJ2CQNMl6jP62D0w4xk7NSO1x-LC8EAk5fVS6D9Tn3TNLDU3MpNRm8XNxGDaLfIrYPSDMaIxB1qRKn-2jG7MVMBOFdVZQZqCUxWJrq8p1-8j1W6daEdOnJ11Fgrvt-82X4jcejJ9d_xAu4PTzY2zW7n_Z3nsIdTqkYMSK0DitnJ7_CMwRIZ-3zqAUXG4AMdQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagSIgLKhRoaAEjVVxQWP8ljk9VaQkLhaoSVFpOVmI7y0pttrTlwI1H4Bn7JMx4vduuQL1tNk5kz3g830zmh5AtwUzLQ8lB0rCFmSubHNRImQvfGNZUgPCja-DzQTk8Uh9HxSjFP52nsMr5mRgPaj916CMfiFIjmCikGXQpLOJwr94-_ZFjByn80praadwmd0BLMmzjoEf6yt_CJJj3KqXoqYqrAaxDvAGJx1ay15RSrN3_P8D5b9zkdTwbFVK9Su4nJEl3Zqx_QG6F_iFZ2-nBij75RV_RGNsZneZrZPwlgF2NxTT6MQXIR1MYB512tMPajI66SaxTe_n7T0wmASBKMQOOwsY8TrmatOk9rd_XQtIJXFD0GgQae-ngi3b39x6Ro_rd191hnlos5E4BdskFqEjVgk4C6soquII5Jlql266UDZivRvCuLHyrAan5UOiuAvjCgQKo6rWu5GOy0k_7sE6o8Z1qtIEBWIKu1VVgpQc8F0IhsYZMRrbmNLans0oaFi0QZIVFVtjIioy8RfovhmD56_jH9GxskzRZb8C2NsEZB_jJNco4OIoawSSAT18ULiObc-7ZJJPn9moHZeTl4jZIE34iafoANMMxEhCY5jDdJzNmL2YiEftqxjOil7bB0lSX7_ST77Fit0HUi0--jhvmpvXbw-E3EX89vXkRL8hdEAD76cPB_ga5JzArg_GcV5tk5eLsZ3gGWOmifR6F4C-tcxCk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Segregating+the+effects+of+ferric+citrate%E2%80%90mediated+iron+utilization+and+FGF23+in+a+mouse+model+of+CKD&rft.jtitle=Physiological+reports&rft.au=Liesen%2C+Michael+P.&rft.au=Noonan%2C+Megan+L.&rft.au=Ni%2C+Pu&rft.au=Agoro%2C+Rafiou&rft.date=2022-06-01&rft.eissn=2051-817X&rft.volume=10&rft.issue=11&rft.epage=n%2Fa&rft_id=info:doi/10.14814%2Fphy2.15307&rft.externalDBID=10.14814%252Fphy2.15307&rft.externalDocID=PHY215307 |